Schering-Plough/Penederm Mentax butenafine cream 1% will reach market in January after Oct. 18 approval.

SCHERING/PENEDERM WILL LAUNCH MENTAX (BUTENAFINE) CREAM 1% IN JANUARY, following the Oct. 18 approval by FDA of the benzylamine antifungal cream for the "topical treatment of interdigital tinea pedis (athlete's foot)." Schering-Plough HealthCare Products will market butenafine to podiatrists in the U.S., while Penederm will promote the drug to dermatologists and primary care physicians.